Lung cancer, a cancer with high global morbidity and mortality rates, is treated in very different ways for different patients. The reasons behind the fact that some people are able to achieve clinical healing while others die in just one year are complex.
Early detection is undoubtedly a key factor influencing the outcome of lung cancer treatment. At an early stage, lung cancer tends to be confined to local areas of the lungs and has yet to undergo long-range transfer. At this point, it is possible to completely remove cancer cells through surgical tumour removal, thus achieving clinical healing. For example, many patients diagnosed with early lung cancer and treated in a timely manner with a relatively high survival rate for the first five years of operation are detected by accident during a medical examination. They may have had only a slight cough or no visible symptoms at an early stage of the disease, precisely because of early precision diagnosis and intervention, which has won valuable opportunities for healing.
The cancer cells may have spread to tissues around the lungs, lymph nodes and even far-off organs, such as liver, bones, brain, etc., for those who are later found. In the case of terminal lung cancer, it is difficult to completely remove the stoves and to control the development of the disease by means of a combination of chemotherapy, treatment, target-to-target treatment or immunotherapy, but these treatments are often difficult to completely remove cancer cells and have greater side effects, with a gradual deterioration of the patient ‘ s physical condition and a significant reduction in the duration of life. Some patients, for example, suffer from chronic neglect of symptoms such as cough, blood, chest pain, or from irregular medical check-ups, which, when diagnosed, are in the advanced stages of lung cancer, which naturally does not work well.
Pathological types and gene mutations also have far-reaching effects on lung cancer treatment outcomes. Lung cancer is mainly classified as small-cell lung cancer and non-small-cell lung cancer, among which non-small-cell lung cancer also includes various subtypes, such as gland cancer and zirconium cancer. Non-small-cell lung cancer patients have the opportunity to use target-based medication if they have specific genetic mutations, such as EGR, ALK, etc. These target-oriented drugs can accurately affect specific target points for cancer cells, inhibit cancer cell growth, have significant and relatively small therapeutic effects and have significantly improved the life and quality of life of patients. On the contrary, small cell lung cancer is highly malignant, growing rapidly, is easily transferable at an early stage, is insensitive to the target drug, has relatively limited treatment and has poor prognosis.
Patients ‘ physical condition and underlying diseases are also factors that cannot be ignored. Patients who are in good physical condition, have normal CPR function and do not have other serious underlying diseases are often better able to withstand the trauma and side effects of various treatments, such as surgery, chemotherapy and treatment. They recover faster after treatment and are able to adapt more quickly to a better state and continue to resist cancer. In addition, patients with a number of basic diseases such as old age, combined heart disease, diabetes and chronic lung disease may experience complications such as infection, heart and lung failure, which can seriously affect the effectiveness of the treatment and even endanger life, leading to shorter life periods when treated for lung cancer.
The treatment of dependent and psychological conditions also plays an important role in the treatment of lung cancer. It is better to control the situation by actively cooperating with the doctor ‘ s treatment programme, taking medication on time and regularly reviewing patients. Patients who have doubts about treatment, who are not on time for treatment or who interrupt treatment on their own are prone to repeated and worsening conditions. The mental state also affects the quality of life and the duration of life of patients, who are optimistic and positive, and whose own immunity and resistance are relatively strong and are more conducive to the fight against cancer; conversely, a person who is chronically in a negative mood, such as anxiety and depression, further weakens the body ‘ s immune function and accelerates progress.
Differences in treatment outcomes for patients with lung cancer are the result of a combination of factors. Early detection, accurate pathological diagnosis and genetic testing, good physical condition, and active therapeutic dependence and psychological state contribute to improving the efficacy of lung cancer treatment and prolonging the patient ‘ s life. It also reminds us of the need to focus on early screening for lung cancer, to improve knowledge about lung cancer, to promote healthy lifestyles to reduce the risk of lung cancer and to achieve better treatment outcomes after the disease.
Lung cancer, small cell lung cancer.
